Follow The Filings

AXSM Axsome Therapeutics

Axsome Therapeutics earnings company data as of 4:45 AM ET 10/31

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 2 Nov EPS -0.64 — —
Rev $250.2M — —

Insider trades

Open-market buys and sales by AXSM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AXSM insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $134M sold by 6 insiders under 10b5-1 plans
  1. Mark L. Jacobson COO
    Planned sale
    $2.1M 10,000 shares at $208.65 100% of stake
    Traded Sep 3 Filed Sep 3
    ↗
  2. Herriot Tabuteau CEO
    Planned sale
    $10.5M 49,664 shares at $212.19 87% of stake
    Traded Aug 5–6 Filed Aug 7
    ↗
  3. Herriot Tabuteau CEO
    Planned sale
    $11.9M 49,666 shares at $240.25 87% of stake
    Traded Jul 1 Filed Jul 1
    ↗
  4. Herriot Tabuteau CEO
    Planned sale
    $12M 49,670 shares at $241.01 87% of stake
    Traded Jun 9 Filed Jun 9
    ↗
  5. Nick Pizzie CFO
    Planned sale
    $7.9M 33,000 shares at $240.09 44% of stake
    Traded Jun 9 Filed Jun 9
    ↗
  6. Mark Coleman Director
    Planned sale
    $4M 17,537 shares at $229.20 37% of stake
    Traded May 29–Jun 2 Filed Jun 2
    ↗
  7. Mark L. Jacobson COO
    Planned sale
    $1.1M 4,750 shares at $227.95 100% of stake
    Traded May 4–5 Filed May 5
    ↗
  8. Ari Maizel Chief Commercial Officer
    Planned sale
    $1.4M 7,500 shares at $182.42 100% of stake
    Traded Apr 22 Filed Apr 23
    ↗
  9. Mark Coleman Director
    Planned sale
    $4M 25,000 shares at $161.11 35% of stake
    Traded Feb 26 Filed Feb 27
    ↗
  10. Mark L. Jacobson COO
    Planned sale
    $5.7M 35,378 shares at $161.88 100% of stake
    Traded Feb 26 Filed Feb 27
    ↗
  11. Herriot Tabuteau CEO
    Planned sale
    $6M 32,410 shares at $185.60 82% of stake
    Traded Feb 2 Filed Feb 2
    ↗
  12. Nick Pizzie CFO
    Planned sale
    $2.3M 12,000 shares at $187.92 22% of stake
    Traded Jan 22 Filed Jan 23
    ↗
  13. Ari Maizel Chief Commercial Officer
    Planned sale
    $1.4M 7,500 shares at $184.44 100% of stake
    Traded Jan 21 Filed Jan 23
    ↗
  14. Herriot Tabuteau CEO
    Planned sale
    $23.9M 139,414 shares at $171.30 95% of stake
    Traded Jan 5–7 Filed Jan 7
    ↗
  15. Mark E Saad Director
    Planned sale
    $6.2M 37,577 shares at $165.18 79% of stake
    Traded Dec 31, 2025 Filed Jan 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 31 option exercises and 5 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.